RNAi Drug Delivery Market Share, Size, Trends and Overview 2021
©
RNAi Drug Delivery Market by Drug Delivery (nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology), by Therapeutic Application (infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders), and by Region –Global Industry Analysis, Share, Size, Growth, Trends, and Forecasts (2016-2021)
Global RNAi Drug Delivery Market was worth USD 24.35 billion in 2016 and is expected to reach USD 81.07 billion by 2021 with a CAGR of 27.2 %. RNAi is a defense mechanism employed by Eukaryotes to degrade exogenous genes such as viruses. It is exclusively called gene silencing. We can initiate this by injecting RNAi-based drugs into the human body which is called RNAi Drug Delivery.
RNAi Drug Delivery is an emerging therapeutic method. This method is specific to the point and has fewer side effects. It is possible to cure cancer with this method by controlling gene mutation. From 2006 onwards various clinical trials are being held and people are investing billions in this market to approve and research various types of RNAi-based Drugs.
Full report at: http://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/
Some factors like increasing prevalence of chronic diseases like cancer and heart diseases and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also amplified the growth in Global RNA Drug Delivery Market. But, High investment and strict regulations are some of the major restraints to this market. Delivery of RNAi Drugs to specific tissues is the key challenge faced by the market.
Global RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into nanoparticle drug delivery technology, nucleic acid drug delivery technology, aptamer drug delivery technology, and pulmonary drug delivery technology. Based on Therapeutic Application, the market is further segmented into infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders. Nanoparticle Drug Delivery is largest sub-segment in this market because of its use in selected delivery of drugs. However, aptamer drug delivery technology is the fastest growing segment.
Market Segmentation:
• Drug delivery
• Therapeutic Application
Key Players:
• Alnylam Pharmaceuticals Inc.
• Merck & Co. Inc
• Access Pharmaceuticals Inc.
Based on Geography, this market is further segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America has the largest share in the market followed by Europe because of their high investments. However, Asia-Pacific market is expected to increase at highest CAGR in the following five years because of increasing investments by the major players in this region
Request sample: http://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/request-sample
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Access Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals Inc, Calondo Pharmaceuticals Inc., Marina Biotech Inc., RXi Pharmaceuticals Corp., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Tacere Therapeutics Inc., Sirnaomics Inc., and PhaseRx Inc.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Global RNAi Drug Delivery Market was worth USD 24.35 billion in 2016 and is expected to reach USD 81.07 billion by 2021 with a CAGR of 27.2 %. RNAi is a defense mechanism employed by Eukaryotes to degrade exogenous genes such as viruses. It is exclusively called gene silencing. We can initiate this by injecting RNAi-based drugs into the human body which is called RNAi Drug Delivery.
RNAi Drug Delivery is an emerging therapeutic method. This method is specific to the point and has fewer side effects. It is possible to cure cancer with this method by controlling gene mutation. From 2006 onwards various clinical trials are being held and people are investing billions in this market to approve and research various types of RNAi-based Drugs.
Full report at: http://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/
Some factors like increasing prevalence of chronic diseases like cancer and heart diseases and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also amplified the growth in Global RNA Drug Delivery Market. But, High investment and strict regulations are some of the major restraints to this market. Delivery of RNAi Drugs to specific tissues is the key challenge faced by the market.
Global RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into nanoparticle drug delivery technology, nucleic acid drug delivery technology, aptamer drug delivery technology, and pulmonary drug delivery technology. Based on Therapeutic Application, the market is further segmented into infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders. Nanoparticle Drug Delivery is largest sub-segment in this market because of its use in selected delivery of drugs. However, aptamer drug delivery technology is the fastest growing segment.
Market Segmentation:
• Drug delivery
• Therapeutic Application
Key Players:
• Alnylam Pharmaceuticals Inc.
• Merck & Co. Inc
• Access Pharmaceuticals Inc.
Based on Geography, this market is further segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America has the largest share in the market followed by Europe because of their high investments. However, Asia-Pacific market is expected to increase at highest CAGR in the following five years because of increasing investments by the major players in this region
Request sample: http://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/request-sample
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Access Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals Inc, Calondo Pharmaceuticals Inc., Marina Biotech Inc., RXi Pharmaceuticals Corp., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Tacere Therapeutics Inc., Sirnaomics Inc., and PhaseRx Inc.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases